{"nctId":"NCT00424476","briefTitle":"A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)","startDateStruct":{"date":"2007-05"},"conditions":["Systemic Lupus Erythematosus"],"count":865,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Belimumab 1 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Belimumab 1 mg/kg"]},{"label":"Belimumab 10 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Belimumab 10 mg/kg"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Belimumab 1 mg/kg","otherNames":["BENLYSTA™ (formerly LymphoStat-B™)"]},{"name":"Belimumab 10 mg/kg","otherNames":["BENLYSTA™ (formerly LymphoStat-B™)"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Clinical diagnosis of SLE by ACR criteria.\n* Active SLE disease.\n* Autoantibody-positive.\n* On stable SLE treatment regimen.\n\nKey Exclusion Criteria:\n\n* Pregnant or nursing\n* Have received treatment with any B cell targeted therapy.\n* Have received treatment with a biological investigational agent in the past year.\n* Have received IV cyclophosphamide within 180 days of Day 0.\n* Have severe lupus kidney disease.\n* Have active central nervous system (CNS) lupus.\n* Have required management of acute or chronic infections within the past 60 days.\n* Have current drug or alcohol abuse or dependence.\n* Have a historically positive test or test positive at screening for HIV, hepatitis B, or hepatitis C.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"SLE Responder Index (SRI) Response Rate at Week 52","description":"Percentage of subjects with a ≥ 4 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of \\< 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.\n\nSELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \\> 20 are rare. PGA is a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.6","spread":null},{"groupId":"OG001","value":"51.4","spread":null},{"groupId":"OG002","value":"57.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Subjects With a ≥ 4 Point Reduction From Baseline in SELENA SLEDAI Score at Wk 52.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.0","spread":null},{"groupId":"OG001","value":"53.1","spread":null},{"groupId":"OG002","value":"58.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Physician's Global Assessment (PGA) at Wk 24.","description":"The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"0.03"},{"groupId":"OG001","value":"-0.44","spread":"0.03"},{"groupId":"OG002","value":"-0.54","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Medical Outcomes 36-Item Short Form Health Survey (SF-36) Physical Component Summary Score (PCS) at Wk 24.","description":"The SF-36 is a generic health related quality of life (HRQOL) measurement. The survey includes 36 questions grouped to 8 domains and 2 summary measures (physical and mental health component, PCS and MCS, respectively) assessing HRQOL. Responses are scored according to the SF-36v2™ manual. A score is calculated for each SF-36 domain based on the patient's response to each question within it. This is then transformed to a scale ranging from 0 (worst) to 100 (best) points. The PCS is norm-based where the mean=50 and standard deviation (SD)=10. Higher scores represent better physical health.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.64","spread":"0.42"},{"groupId":"OG001","value":"3.65","spread":"0.43"},{"groupId":"OG002","value":"3.58","spread":"0.46"}]}]}]},{"type":"SECONDARY","title":"Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline to ≤ 7.5 mg/Day During Weeks 40 Through 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null},{"groupId":"OG001","value":"20.6","spread":null},{"groupId":"OG002","value":"18.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Events (AE) Overview","description":"SEE ALSO ADVERSE EVENTS RESULTS SECTION","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.6","spread":null},{"groupId":"OG001","value":"91.7","spread":null},{"groupId":"OG002","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"16.3","spread":null},{"groupId":"OG002","value":"14.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.7","spread":null},{"groupId":"OG002","value":"1.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":287},"commonTop":["Headache","Upper respiratory tract infection","Arthralgia","Influenza","Diarrhoea"]}}}